

Initial findings from a first-in-human, multicenter, open-label study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies

ASCO 2022 Poster 2529

- infiltrating the tumor.
- recurrence.








- potentially reducing the risk of exaggerated biology.
- No safety concerns were demonstrated in non-human primate toxicity studies [1] and preclinical


- 2 dose.
- anti-tumor activity of ATOR-1017.





Gustav J. Ullenhag¹*, Ana Carneiro², Karin Enell Smith³, Lena Schultz³, Sumeet Ambarkhane³, Tova Landström^{3**}, Jeffrey Yachnin⁴ 1 Uppsala University Hospital, Uppsala, Sweden; 2 Skane University Hospital and Lund University, Lund, Sweden; 3 Alligator Bioscience AB, Lund, Sweden; 3 Alligator Biosci

	ATOR-1017 dose level (mg)						
	0.38 - 15	40	100	200	360	600	Overall
nts	4	3	3	3	6	3	22
TEAEs	4 (100)	3 (100)	3 (100)	3 (100)	6 (100)	3 (100)	22 (100)
Grade 3 or 4	1 (25)	2 (66.7)	0	2 (66.7)	5 (83.3)	2 (66.7)	12 (54.5)
TRAEs	2 (50)	3 (100)	1 (33.3)	1 (33.3)	3 (50)	2 (66.7)	12 (54.5)
Grade 3 or 4	0	1 (33.3)	0	1 (33.3)	2 (33.3)	1 (33.3)	5 (22.7)

Pharmacokinetics







Data is presented as maximum fold-change from baseline in cycle 1

- > In this FiH study, ATOR-1017 has been dosed up to 600 mg and demonstrates an encouraging safety profile and indications of clinical benefit.
- > No DLTs were observed and the MTD has not been reached.
- Most TRAEs were mild to moderate (severity Grade 1 or 2).
- ATOR-1017 exhibits a favorable PK profile.
- > Activation of peripheral T cells and increased levels of soluble 4-1BB was observed across active dose levels of ATOR-1017, demonstrating biological activity and proof of mechanism.
- The study is ongoing at the 900 mg dose level.

ACKNOWLEDGEMENTS: The patients and their families. The study investigators and members of the clinical study team. Alligator Bioscience AB, the study sponsor, and the clinical study team at Alligator.

REFERENCES:

- Immunology Research 7 (Suppl 2) A183-A183.
- ImmunoTherapy of Cancer 9 (Suppl 2) A595-A595.
- ImmunoTherapy of Cancer 9 (Suppl 1) 55-55.

Copies of this poster obtained through Quick Response (QR) Code are for personal use only and may not be reproduced without permission from ASCO® and the author of this poster.

CONCLUSIONS

1) Dahlén, E., et al. (2019) ATOR-1017: A 4-1BB antibody designed for superior safety/efficacy profile in cancer immunotherapy, Cancer

2) Smith, K. E., et al. (2021) ATOR-1017, a second generation 4–1BB antibody with potential to enhance efficacy of PD-1 therapies, Journal for

3) Werchau, D., et al. (2019) ATOR-1017, a 4-1BB antibody developed for tumor-directed immunotherapy of cancer, Journal for

